Microbial Profiles in the Gut and Their Association with Immunotherapy Efficacy in Non-Small Cell Lung Cancer and Melanoma: A Comprehensive Review and Meta-Analysis - Scorecard - MDSpire
Advertisement
Microbial Profiles in the Gut and Their Association with Immunotherapy Efficacy in Non-Small Cell Lung Cancer and Melanoma: A Comprehensive Review and Meta-Analysis
Clinical Scorecard: Microbial Profiles in the Gut and Their Association with Immunotherapy Efficacy in Non-Small Cell Lung Cancer and Melanoma: A Comprehensive Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Non-Small Cell Lung Cancer and Melanoma
Key Mechanisms
Gut microbiome influences systemic immune responses and efficacy of immune checkpoint inhibitors.
Target Population
Adult patients (≥ 18 years) with NSCLC or melanoma treated with ICIs.
Care Setting
Oncology clinics administering immunotherapy.
Key Highlights
Gut microbiome diversity correlates with improved responses to ICIs.
Specific bacterial taxa such as Faecalibacterium and Akkermansia muciniphila are associated with better outcomes.
Primary and acquired resistance to ICIs remains a significant challenge.
Guideline-Based Recommendations
Diagnosis
Confirm diagnosis of NSCLC or melanoma.
Assess gut microbiome composition at baseline.
Management
Consider gut microbiome profiling to optimize ICI therapy.
Monitoring & Follow-up
Monitor for immune-related adverse events (irAEs) during treatment.
Risks
Potential for treatment discontinuation due to irAEs.
Patient & Prescribing Data
Patients with advanced NSCLC or melanoma receiving ICIs.
Microbiome characteristics may serve as novel biomarkers for predicting ICI efficacy.
Clinical Best Practices
Incorporate microbiome analysis in treatment planning for NSCLC and melanoma patients.
Utilize established biomarkers alongside microbiome data for patient selection.
